• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    ReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets

    6/12/25 8:25:20 AM ET
    $RSLS
    Medical/Dental Instruments
    Health Care
    Get the next $RSLS alert in real time by email

    IRVINE, Calif., June 12, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the signing of an exclusive U.S. distribution agreement with Recon Supply. Through this new strategic partnership, Recon Supply will distribute ReShape's cutting-edge portfolio, including the STIMEL-03 neuromuscular rehabilitation device, the next-generation Lap-Band® 2.0 FLEX, and the full range of ReShape products, across the Veterans Administration (VA) and Department of Defense (DoD) healthcare systems. This collaboration will expand access to proven, life-changing treatments for more than 18 million U.S. veterans and active military personnel.

    "This agreement with Recon Supply marks a pivotal step forward in ReShape's mission to expand access to innovative medical technologies that improve lives," stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences. "Through Recon's extensive footprint across the VA and DoD healthcare systems, we look forward to bringing our FDA-cleared STIMEL-03 system, a cutting-edge neurorehabilitation platform that is transforming clinical care with real-time EMG biofeedback and personalized electrical stimulation, to veterans and military personnel recovering from stroke, injury, or surgery. Additionally, the Lap-Band® 2.0 FLEX, our next-generation, minimally invasive weight loss solution, offers a safe, adjustable option for individuals struggling with obesity. Together, these technologies reflect our commitment to delivering high-impact, clinically proven solutions to patients in need, including those who have served our country."

    "Partnering with ReShape Lifesciences aligns perfectly with our mission to deliver innovative, life-changing medical solutions to those who have served our country," added Steve Clark, Chief Executive Officer of Recon Supply and a U.S. Marine Corps veteran. "With established access to VA and DoD facilities through our Distribution and Pricing Agreement (DAPA), Federal Supply Schedule (FSS), and Electronic Catalog (ECAT) contracts, this agreement allows us to expand the reach of ReShape's most impactful technologies—including the STIMEL-03 rehabilitation system and the Lap-Band® 2.0 FLEX. These solutions are well-suited to the complex needs of the veteran and active-duty populations we serve. Since relaunching in 2022, Recon Supply has grown over 113% year-over-year and now distributes to 102 VA Medical Centers nationwide, with a team made up almost entirely of veterans and veteran spouses. We are proud to partner with ReShape to bring these vital solutions to the men and women who have sacrificed for our country."

    About Recon Supply

    Recon Supply is a trusted distributor of medical products and technologies, specializing in providing high-quality solutions to federal agencies and healthcare systems. As a Service-Disabled Veteran-Owned Small Business (SDVOSB), Recon Supply is dedicated to delivering the most innovative medical technologies while actively supporting the veteran community through hiring initiatives. With a focus on excellence and reliability, Recon Supply is committed to enhancing patient care through innovative partnerships. For more information on Recon Supply, visit www.Recon-Supply.com

    About ReShape Lifesciences®

    ReShape Lifesciences® is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The investigational vagal neuromodulation system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of type 2 diabetes and metabolic disorders. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit www.reshapelifesciences.com.

    Forward-Looking Safe Harbor Statement

    This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," other words of similar meaning and the use of future dates. Forward-looking statements in this press release include statements about the expectations regarding the distribution arrangement of Recon Supply. These and additional risks and uncertainties are described more fully in the company's filings with the Securities and Exchange Commission, including those factors identified as "risk factors" in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.

    CONTACTS

    ReShape Lifesciences Investor Contact:

    Paul F. Hickey

    President and Chief Executive Officer

    949-276-7223

    [email protected]

    Investor Relations Contact:

    Rx Communications Group

    Michael Miller

    (917)-633-6086

    [email protected]



    Primary Logo

    Get the next $RSLS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RSLS

    DatePrice TargetRatingAnalyst
    10/8/2021$8.00Buy
    Maxim Group
    More analyst ratings

    $RSLS
    Leadership Updates

    Live Leadership Updates

    See more
    • ReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio

      IRVINE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Quality Management System (QMS) and entire commercial portfolio of medical devices sold in Europe and in the United Kingdom (UK) have been certified under the European Union (EU) Medical Device Regulation (MDR) (EU) 2017/745 and UK Conformity Assessment (UKCA), respectively. The EU MDR, which replaced the Medical Device Directive (MDD) in May 2021, sets significantly more stringent requirements for clinical evaluation, post-market surveillance, and device traceability. Its goal is to improve patient sa

      6/3/25 8:31:00 AM ET
      $RSLS
      Medical/Dental Instruments
      Health Care
    • ReShape Lifesciences Appoints Seasoned Sales and Marketing Executive, Nick Ansari, as Senior Vice President of Global Commercial Operations

      SAN CLEMENTE, Calif., Aug. 23, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the company has appointed Nick Ansari as Senior Vice President of Global Commercial Operations, effective September 6, 2022. Mr. Ansari, who, from 2014 to 2019 was Senior Vice President Global Sales for Enteromedics, the predecessor company to Reshape, will be responsible for strengthening the executional efficiencies of the sales and marketing team, worldwide. In this role, he will report directly to Mr. Paul F. Hickey, ReShape's President and Chief Executive Officer. "Nick is a proven executive

      8/23/22 8:30:00 AM ET
      $RSLS
      Medical/Dental Instruments
      Health Care
    • ReShape Lifesciences Announces Appointment of Paul F. Hickey as President and Chief Executive Officer

      SAN CLEMENTE, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Board of Directors has appointed Paul F. Hickey as President and Chief Executive Officer and as a member of the Board of Directors, effective August 15, 2022. Mr. Hickey succeeds Bart Bandy, who has separated from the company to pursue other opportunities. Thomas Stankovich, Chief Financial Officer of ReShape, will serve as Interim President and Chief Executive Officer until Mr. Hickey joins the company. Dan W. Gladney, current Chair of the Board of Directors, will assume a more active role as Exe

      7/27/22 4:05:00 PM ET
      $RSLS
      Medical/Dental Instruments
      Health Care

    $RSLS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets

      IRVINE, Calif., June 12, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the signing of an exclusive U.S. distribution agreement with Recon Supply. Through this new strategic partnership, Recon Supply will distribute ReShape's cutting-edge portfolio, including the STIMEL-03 neuromuscular rehabilitation device, the next-generation Lap-Band® 2.0 FLEX, and the full range of ReShape products, across the Veterans Administration (VA) and Department of Defense (DoD) healthcare systems. This collaboration will expand access to proven, life-changing treatments for more than 18 million U.S. ve

      6/12/25 8:25:20 AM ET
      $RSLS
      Medical/Dental Instruments
      Health Care
    • ReShape Lifesciences® Announces Pricing of $2.6 Million Public Offering

      IRVINE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® ("ReShape" or the "Company") (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the pricing of its public offering of 1,054,604 shares of common stock at a public offering price of $2.50 per share. Gross proceeds from the offering are expected to be approximately $2.6 million before deducting placement agent fees and other offering expenses. The offering is expected to close on or about June 9, 2025, subject to the satisfaction of customary closing conditions. Maxim Group LLC is acting as sole placement agent in connection with the offering. The public offerin

      6/9/25 9:00:00 AM ET
      $RSLS
      Medical/Dental Instruments
      Health Care
    • ReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio

      IRVINE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its Quality Management System (QMS) and entire commercial portfolio of medical devices sold in Europe and in the United Kingdom (UK) have been certified under the European Union (EU) Medical Device Regulation (MDR) (EU) 2017/745 and UK Conformity Assessment (UKCA), respectively. The EU MDR, which replaced the Medical Device Directive (MDD) in May 2021, sets significantly more stringent requirements for clinical evaluation, post-market surveillance, and device traceability. Its goal is to improve patient sa

      6/3/25 8:31:00 AM ET
      $RSLS
      Medical/Dental Instruments
      Health Care

    $RSLS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Reshape Lifesciences with a new price target

      Maxim Group initiated coverage of Reshape Lifesciences with a rating of Buy and set a new price target of $8.00

      10/8/21 9:13:24 AM ET
      $RSLS
      Medical/Dental Instruments
      Health Care

    $RSLS
    Financials

    Live finance-specific insights

    See more

    $RSLS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $RSLS
    SEC Filings

    See more

    $RSLS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

      IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the third quarter ended September 30, 2024, including a corporate update on Thursday, November 14, 2024, after market. Management will host a conference call on Thursday, November 14 at 4:30 pm ET, and will be joined by Krishna K. Gupta, a current Director of Vyome Therapeutics, who will be appointed Chairman of the combined company upon completion of the previously announced merger agreement between the two companies. A live webcast will be available on the

      11/12/24 4:05:00 PM ET
      $RSLS
      Medical/Dental Instruments
      Health Care
    • ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

      IRVINE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the second quarter ended June 30, 2024, including a corporate update on Wednesday, August 14, 2024, after market. Management will host a conference call on August 15 at 4:30 pm ET, and will be joined by Krishna K. Gupta, a current Director of Vyome Therapeutics, who will be appointed Chairman of the combined company upon completion of the previously announced merger agreement between the two companies. A live webcast will be available on the "Events and Presenta

      8/13/24 8:31:00 AM ET
      $RSLS
      Medical/Dental Instruments
      Health Care
    • ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update

      Commercial Launch of Next-Generation Lap-Band® 2.0 FLEX Continues Significant Reduction in Overall Operating Expenses of 51% in the First Quarter of 2024 Compared to the First Quarter of 2023 Implementation of 2024 Cost Reduction Plan Continues, Expected to Reduce Operating Expenses by 55.4% Compared to 2023 Conference Call to be Held at 4:30 pm ET Today IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the first quarter ended March 31, 2024 and provided a corporate strategic update. First Quarter 2024 and Subsequent Highlights Ma

      5/15/24 4:05:00 PM ET
      $RSLS
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Stankovich Thomas sold $39 worth of shares (172 units at $0.23), decreasing direct ownership by 0.75% to 22,777 units (SEC Form 4)

      4 - ReShape Lifesciences Inc. (0001427570) (Issuer)

      8/13/24 4:29:13 PM ET
      $RSLS
      Medical/Dental Instruments
      Health Care
    • New insider Schneid Yair claimed ownership of 2,461,000 shares (SEC Form 3)

      3 - ReShape Lifesciences Inc. (0001427570) (Issuer)

      1/16/24 6:11:06 PM ET
      $RSLS
      Medical/Dental Instruments
      Health Care
    • Stankovich Thomas sold $386 worth of shares (435 units at $0.89), decreasing direct ownership by 2% to 22,949 units (SEC Form 4)

      4 - ReShape Lifesciences Inc. (0001427570) (Issuer)

      11/8/23 4:16:25 PM ET
      $RSLS
      Medical/Dental Instruments
      Health Care
    • SEC Form SCHEDULE 13G filed by ReShape Lifesciences Inc.

      SCHEDULE 13G - ReShape Lifesciences Inc. (0001427570) (Subject)

      6/13/25 4:05:27 PM ET
      $RSLS
      Medical/Dental Instruments
      Health Care
    • ReShape Lifesciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ReShape Lifesciences Inc. (0001427570) (Filer)

      6/12/25 4:18:45 PM ET
      $RSLS
      Medical/Dental Instruments
      Health Care
    • SEC Form 424B5 filed by ReShape Lifesciences Inc.

      424B5 - ReShape Lifesciences Inc. (0001427570) (Filer)

      6/9/25 11:31:15 AM ET
      $RSLS
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ReShape Lifesciences Inc.

      SC 13G/A - ReShape Lifesciences Inc. (0001427570) (Subject)

      9/26/24 4:45:20 PM ET
      $RSLS
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D filed by ReShape Lifesciences Inc.

      SC 13D - ReShape Lifesciences Inc. (0001427570) (Subject)

      3/17/23 5:01:18 PM ET
      $RSLS
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D filed by ReShape Lifesciences Inc.

      SC 13D - ReShape Lifesciences Inc. (0001427570) (Subject)

      2/15/23 3:34:19 PM ET
      $RSLS
      Medical/Dental Instruments
      Health Care